SL651498, a GABAAReceptor Agonist with Subtype‐Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
SL651498 (6‐fluoro‐9‐methyl‐2‐phenyl‐4‐(pyrrolidin‐1‐yl‐carbonyl)‐2, 9‐dihydro‐1 H‐pyrido[3,4‐b]indol‐1‐one) was identified as a drug development candidate from a research program designed to discover subtype‐selective GABA A receptor agonists for the treatment of generalized anxiety disorder and muscle spasms. The drug displays high affinity for rat native GABA A receptors containing α 1(Ki= 6.8 nM) and α 2(Ki= 12.3 nM) subunits, and weaker affinity for α 5‐containing GABA A receptors (Ki= 117 nM). Studies on recombinant rat GABA A receptors confirm these findings and indicate intermediate affinity for the α 3 β 2 γ 2 subtype. SL651498 behaves as a full agonist at recombinant rat GABA A receptors containing α 2 and α 3 subunits, and as a partial agonist at recombinant GABA A receptors expressing α 1 and α 5 subunits. SL651498 produced anxiolytic‐like and skeletal muscle relaxant effects qualitatively similar to those of benzodiazepines (BZs) [minimal effective dose (MED): 1 to 10 mg/kg, i.p. and 3 to 10 mg/kg, p.o.]. However, unlike these latter drugs, SL651498 induced muscle weakness, ataxia or sedation at doses much higher than those having anxiolytic‐like activity (MED: 30 to 100 mg /kg, i.p. or p.o.). Moreover, in contrast to BZs, SL651498 did not produce tolerance to its anticonvulsant activity or physical dependence. It was much less active than BZs in potentiating the depressant effects of ethanol or impairing cognitive processes in rodents. The differential profile of SL651498 as compared to BZs may be related to its selective efficacy at the α 2 and α 3‐containing GABA A receptors. This suggests that selectively targeting GABA A receptor subtypes can lead to drugs with increased clinical specificity. SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding
Braestrup, C., & Squires, R. F. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.9.3805 · Cited by 1,264
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · cited 2×
“This suggests that selectively targeting GABAA receptor subtypes can lead to drugs with increased clinical specificity (31).”
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
A new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×
“The functional selectivity of SL651498 for á2 and á3 GABAA receptor subtypes in the spinal cord (14), where they have been suggested to play an important role in the muscle relaxant effects of benzodiazepines (37), prompted us to investigate the effects of SL651498 in a variety of animal models predictive of muscle re…”
Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.
Perrault, G., Morel, E., Sanger, D. J., & Zivkovic, B. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10339-x · Cited by 110
Self-citationBenzodiazepines alter acquisition and retention of an inhibitory avoidance response in mice
Jensen, R. A., Martinez, J. L., Vasquez, B. J., & McGaugh, J. L. (1979) · Psychopharmacology · doi:10.1007/bf00427358 · Cited by 79 · cited 1×
“In animal procedures, BZs can induce disturbances in learning (6,25,55).”
Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Françon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29437-4 · Cited by 59 · cited 6×
“5), together with the finding that the former antagonized the anti-isoniazid effects of diazepam and zolpidem (19) strengthens the electrophysiological data showing that SL651498 behaves in vivo as a partial agonist at GABAA receptor subtypes expressing á1 subunits.”
InfluentialSelf-citation
Cited by
GABAA receptors: Subtypes provide diversity of function and pharmacology
Olsen, R. W., & Sieghart, W. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.045 · Cited by 982
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499
GABAA receptor diversity and pharmacology
Möhler, H. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0284-3 · Cited by 363
Structure, Pharmacology, and Function of GABAA Receptor Subtypes
Sieghart, W. (2006) · Advances in Pharmacology · doi:10.1016/s1054-3589(06)54010-4 · Cited by 317
Metadata
- Authors
- Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Depoortere, H., Françon, D., Avenet, P., Schoemaker, H., Evanno, Y., Sevrin, M., George, P., & Scatton, B.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 9
- Issue
- 1
- Pages
- 3-20
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W1971227264
- Cited by
- 76
- References
- 8
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SL651498, a GABAAReceptor Agonist with Subtype‐Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms. https://app.cochat.ai/papers/10.1111/j.1527-3458.2003.tb00241.x
- The paper
- Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Depoortere, H., Françon, D., Avenet, P., Schoemaker, H., Evanno, Y., Sevrin, M., George, P., & Scatton, B. (2003). SL651498, a GABAAReceptor Agonist with Subtype‐Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2003.tb00241.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.